Covid Safe & Energy Efficient Ventilation
Covid Safe & Energy Efficient Ventilation
批准号:
78319
负责人:
金额:
$32.99万
依托单位:
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2020
资助国家:
英国
项目状态:
已结题
起止时间:
2020 至 --
中文摘要
2019冠状病毒病已经搁置了通风系统的能源效率和脱碳,政府指导方针建议采取碳和能源惩罚措施,为居住者提供安全和清洁的空气。这对可持续发展和脱碳目标造成了重大影响。此外,新冠肺炎疫情给该行业带来了巨大的财务和运营冲击,导致升级项目、研发和效率措施暂停。这对我们的企业和其他许多企业都产生了直接影响。空气处理机组和相关的供暖、通风和空调(HVAC)系统是建筑领域最大的单一成本能源消耗者,约占33%。热量大约。平均商业建筑碳排放量的50%。由于热量是实现净零排放的三大关键支柱之一,目前的COVID-19通风指南对到2050年实现长期净零排放和气候紧急目标具有重大影响。因此,找到解决这一低效通风问题的解决方案至关重要。我们的**Covid安全和节能通风**项目旨在解决导致这种情况的两个主要驱动因素:安全重新开放建筑物和提高企业生产力的需要;每天在家。减少能源消耗,从而降低服务费,并通过节省能源获得投资回报,从而收回成本,并有助于留住租户或吸引新租户。我们的目标是通过将最先进的、节能的、动态的HVAC控制措施(由该团队先前开发)与来自医疗保健行业的最先进的病原体抑制技术相结合来实现这一目标。我们预计这种方法将产生一种产品组合,不仅能够超过大流行和大流行后安全的指导要求,而且还能降低暖通空调成本。需要研究将这些技术结合起来,特别是在非医疗建筑中。建筑用户还需要通过感知和已知策略获得信心,以便安全有效地恢复运营。我们已经为我们与合作伙伴公司的研发试验确定了一个地点,该公司热衷于成为早期采用者。这将使我们能够评估技术组合及其有效性。它还将促进对传感和控制技术的研究,以优化病原体控制、再循环和加热负荷。我们的团队提供了一个前所未有的公司集团,拥有知识产权和商标,以现有的暖通空调方法运作。我们还拥有丰富的研发和商业实施经验,在HVAC和更广泛的绿色能源市场将新技术推向英国市场方面有着良好的记录。英国AHU市场估计每年为170亿英镑,对碳排放和成本都有巨大影响。这是一个巨大的机会,可以解决新冠肺炎带来的通风效率低下问题,并支持英国经济安全重返工作岗位。通过我们目前的客户和合作伙伴网络,我们已经确定了一些有兴趣成为这种方法的早期采用者的客户和团体。这包括大型私人公司和理事会机构。
英文摘要
COVID-19 has put energy efficiency and decarbonisation in ventilation systems on hold, through government guidelines suggesting taking carbon and energy penalties to deliver safe and clean air for occupants. This has caused a significant impact on sustainability and decarbonisation goals. Furthermore, the industry has taken huge financial and operational hits from COVID-19, leading to a pause on upgrade projects, R&D and efficiency measures. This has had a direct effect on our businesses and many others.Air Handling Units and related Heating, Ventilation and Air Conditioning (HVAC) systems constitute the largest single cost energy consumer in the building sector at around 33%. With heat making up approx. 50% of the average commercial building carbon emissions. As heat is one of the 3 key pillars to address in achieving net zero the current COVID-19 ventilation guidance presents a significant major impact on long term net zero by 2050 and climate emergency targets.Thus, it is critical that solutions are found to address this inefficient ventilation problem. Our **Covid Safe & Energy Efficient Ventilation** Project is designed to address two main drivers resulting from this situation:1.The need to reopen buildings safely and increasing business productivity; and2.To reduce energy consumption, therefore reduce service charge, and offer a return on investment through energy saving that will pay for itself and help retain tenants or attract new tenants.We aim to enable this by combining state-of-the-art, energy efficient, dynamic HVAC control measures (developed previously by this team), with state-of-the-art pathogen inhibiting technologies taken from the healthcare industry. We anticipate this approach will produce a product combination not only capable of exceeding the guideline requirements for pandemic and post-pandemic safety but also reducing HVAC costs.Research is required to combine these technologies, especially in non-medical buildings. Building users also need confidence via sensing and known strategies in order to enable a safe and efficient return to operation.We have a location defined for our R&D trials with a partner company, who is keen to be an early adopter. This will allow us to assess the technology combinations and their effectiveness. It will also enable research into sensing and control techniques to optimise pathogen control, recirculation and heating loads.Our team presents an unprecedented group of companies with both the IP and trademarks to operate with the existing HVAC approach. We also have extensive R&D and commercial implementation experience with a proven track record of bringing new technologies to market across the UK, in both HVAC and broader green energy markets.The UK AHU market is estimated at £17bn per year and has a huge effect on both carbon emission and cost. This represents a huge opportunity to address the inefficient ventilation problem brought about by COVID-19 and support the UK economy in returning to work safely.Through our current network of clients and partners, we have identified several clients and groups who are interested in becoming early adopters of this approach. This includes large private companies and council bodies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
叶绿体蛋白SAFE1和SAFE2介导单线态氧信号转导的机理研究
-
批准号:32170284
-
项目类别:面上项目
-
资助金额:60万元
-
批准年份:2021
-
负责人:王良省
-
依托单位:
基于Safe screening的多任务稀疏学习理论与算法的研究
-
批准号:12071475
-
项目类别:面上项目
-
资助金额:51.0万元
-
批准年份:2020
-
负责人:徐义田
-
依托单位:
醛糖还原酶(AR)激活SAFE(JAKs/STATs)通路在抵抗下颌下腺缺血再灌注损伤中的作用
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:张思恩
-
依托单位:
基于Safe screening 的支持向量机的稀疏理论及其快速求解方法
-
批准号:11671010
-
项目类别:面上项目
-
资助金额:48.0万元
-
批准年份:2016
-
负责人:徐义田
-
依托单位:
Notch1与RISK/SAFE/HIF-1α信号通路整合在I-postC保护中的作用及其机制
-
批准号:81260024
-
项目类别:地区科学基金项目
-
资助金额:50.0万元
-
批准年份:2012
-
负责人:刘季春
-
依托单位:
氙气延迟后处理对兔脊髓缺血再灌注损伤的保护作用及SAFE细胞信号机制研究
-
批准号:81271387
-
项目类别:面上项目
-
资助金额:70.0万元
-
批准年份:2012
-
负责人:程卫平
-
依托单位: